OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit www.conferenceseries.com

Back

Takashi Kei Kishimoto

Takashi Kei Kishimoto

Selecta Biosciences, USA

Selecta Biosciences
USA

Biography

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, he was Vice President of Research at Momenta Pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products. Previously he held leadership positions at Millennium Pharmaceuticals and Boehringer Ingelheim. Dr. Kishimoto has published over 50 peer-reviewed articles, including articles in Nature, Science, Cell, and the New England Journal of Medicine. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Research

Nanoparticle-based vaccines for chronic diseases